Novartis, Ionis will work together again in the next-generation cardio space

No­var­tis is once again team­ing up with Io­n­is on a next-gen­er­a­tion siR­NA car­dio drug, pick­ing up an­oth­er shot in an in­creas­ing­ly com­pet­i­tive space.

The deal cen­ters around car­dio­vas­cu­lar dis­ease dri­ven by lipopro­tein(a), or Lp(a), a fat-trans­port mol­e­cule that is es­ti­mat­ed to in­crease CVD risk by 20% to 30% of the glob­al pop­u­la­tion. Io­n­is will get $60 mil­lion in up­front cash for the as-yet un­named drug, and will be el­i­gi­ble for an undis­closed amount of mile­stone pay­ments, ac­cord­ing to a press re­lease.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters